Overexpression of SOX11 promotes the development of mantle cell lymphoma

 It is the first time described in vivo (in animals) oncogenic factor SOX11 protein, a  transcription factor involved in the development and aggressiveness of lymphoma  mantle cell, one of the most aggressive non-Hodkings lymphomas are. Because it is very  difficult to treat, the research community is particularly interested in identifying  therapeutic targets to address a disease whose survival does not exceed 3-5 years. This  is the case of Dr. Virginia Amador, researcher in the area of human and experimental  functional oncomorphology IDIBAPS, submitted last February 6 the results of their  research work focused on the molecule SOX11. Under the title of the seminar Functional  analysis of SOX11 in mantle cell lymphoma, Virginia showed that overexpression of the  transcription factor SOX11 not only promotes the creation and progression of mantle  cell lymphoma, but is also involved in the aggressiveness of it. This makes it the perfect  therapeutic target to inhibit cancer development. The results are published by the  journal Blood.

"We discovered that SOX11 activates two ways: on one hand, inhibits the differentiation of lymphoma cells blocking them mantle in a state of naive cells, and secondly, stimulates angiogenesis through PDGFA, a molecule that plays a fundamental role in tumor growth", says Amador. "If we block the two pathways we could inhibit the development of breast cancer". The next step is to test the ability of these inhibitors to block the effect of oncogenic human SOX11.

Article Reference:

Vegliante MC, Palomero J, Pérez-Galán P, Roué G, Castellano G, Navarro A, Clot G, Moros A, Suárez-Cisneros H, Beà S, Hernández L, Enjuanes A, Jares P, Villamor N, Colomer D, Martín-Subero JI, Campo E, Amador V. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013 Mar 21;121(12):2175-85. doi: 10.1182/blood-2012-06-438937. Epub 2013 Jan 15.